AU2022367394B2 - Engineered tgf-beta monomers and methods of use - Google Patents

Engineered tgf-beta monomers and methods of use

Info

Publication number
AU2022367394B2
AU2022367394B2 AU2022367394A AU2022367394A AU2022367394B2 AU 2022367394 B2 AU2022367394 B2 AU 2022367394B2 AU 2022367394 A AU2022367394 A AU 2022367394A AU 2022367394 A AU2022367394 A AU 2022367394A AU 2022367394 B2 AU2022367394 B2 AU 2022367394B2
Authority
AU
Australia
Prior art keywords
tgf
seq
amino acid
substitution
monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022367394A
Other languages
English (en)
Other versions
AU2022367394A1 (en
Inventor
Greg M. Delgoffe
Kristin DEPEAUX
Andrew P. HINCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU2022367394A1 publication Critical patent/AU2022367394A1/en
Application granted granted Critical
Publication of AU2022367394B2 publication Critical patent/AU2022367394B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2022367394A 2021-10-11 2022-10-11 Engineered tgf-beta monomers and methods of use Active AU2022367394B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254249P 2021-10-11 2021-10-11
US63/254,249 2021-10-11
PCT/US2022/077879 WO2023064747A1 (en) 2021-10-11 2022-10-11 Engineered tgf-beta monomers and methods of use

Publications (2)

Publication Number Publication Date
AU2022367394A1 AU2022367394A1 (en) 2024-04-11
AU2022367394B2 true AU2022367394B2 (en) 2026-03-19

Family

ID=85988028

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022367394A Active AU2022367394B2 (en) 2021-10-11 2022-10-11 Engineered tgf-beta monomers and methods of use

Country Status (9)

Country Link
US (1) US20240425559A1 (enExample)
EP (1) EP4416172A4 (enExample)
JP (1) JP2024537234A (enExample)
KR (1) KR20240082356A (enExample)
CN (1) CN118103390A (enExample)
AU (1) AU2022367394B2 (enExample)
CA (1) CA3232809A1 (enExample)
TW (1) TW202330579A (enExample)
WO (1) WO2023064747A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018094173A1 (en) * 2016-11-18 2018-05-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
WO2022047220A1 (en) * 2020-08-27 2022-03-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses encoding recombinant tranforming growth factor (tgf)-beta monomers and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018094173A1 (en) * 2016-11-18 2018-05-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
WO2022047220A1 (en) * 2020-08-27 2022-03-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses encoding recombinant tranforming growth factor (tgf)-beta monomers and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kim, S.K. et al., 2017. An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative to block TGF-β signaling. Journal of Biological Chemistry, 292(17), pp.7173-7188. *

Also Published As

Publication number Publication date
KR20240082356A (ko) 2024-06-10
TW202330579A (zh) 2023-08-01
CN118103390A (zh) 2024-05-28
AU2022367394A1 (en) 2024-04-11
CA3232809A1 (en) 2023-04-20
JP2024537234A (ja) 2024-10-10
WO2023064747A1 (en) 2023-04-20
EP4416172A4 (en) 2025-12-17
US20240425559A1 (en) 2024-12-26
EP4416172A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
US12428460B2 (en) Engineered TGF-beta monomers and their use for inhibiting TGF-beta signaling
JP6279788B2 (ja) 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
US11033609B2 (en) Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
AU2022367394B2 (en) Engineered tgf-beta monomers and methods of use
US20220023395A1 (en) Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
CN102993314A (zh) 一种抗肿瘤融合蛋白及其制备方法和用途
WO2008120263A2 (en) Prokineticins receptors antagonists, derivatives and uses thereof
HK40109585A (zh) 工程化TGF- β单体及其使用方法
WO2016097753A1 (en) Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis
JP7375163B2 (ja) Ｔｇｆ－ベータトラップ
KR20150010957A (ko) 넓은 스펙트럼 erbb 리간드 결합 분자 및 그의 사용 방법
CN110520144A (zh) 肽激酶抑制剂及其使用方法
WO2025217401A1 (en) A peptide inhibitor of the eya and pp2a-b55a interaction useful for myc-driven cancer therapy
CA3041727C (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
HK40100217A (zh) 无催化活性的梭菌神经毒素用於疼痛和炎性疾病的治疗
WO2020067389A1 (ja) 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬
HK40015109A (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling